Study: NCT02659735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 300 milligram (mg)
Description: Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 600 mg
Description: Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.